Rhinomed is an airway technology company that seeks to radically improve the way you breathe, sleep, maintain your health and take medication.
Rhinomed’s patented nasal technology leverages the physiology of the nose to optimise our breathing which is essential to restful sleep and to maintaining good health.
Rhinomed’s vision for the future is to enable medications to be administered through the nose with the aim of improving the efficiency and effectiveness of the therapies, while seeking a reduction in side effects for patients.
Rhinomed continues to invest in furthering our knowledge of the role the nose, the upper airways and the olfactory system plays in maintaining health and wellness.
Rhinomed’s technology platform is protected by a family of over 60 patents globally. Rhinomed is listed on the Australian Stock Exchange (ASX: RNO) and headquartered in Melbourne, Australia.
Rhinomed’s nasal technology platform seeks to optimise the role the nose plays in your body’s physiology and the maintenance of good health. The technology platform aims to address significant unmet needs across four key areas of opportunity.
The Rhinomed platform is protected by a family of over 60 patents. These are granted and pending across the global market. Rhinomed continues to invest in furthering our knowledge of the role the nose, the upper airway and the olfactory system plays in maintaining health and wellness.
Rhinomed is actively seeking to partner with companies, research institutions and organisation whose interest coincide. Please reach out to us.
Board & Management
Rhinomed is led by a globally experienced team.
Managing Director & CEO
Michael is an experienced leader and innovator with a focus on the successful commercialisation of emerging technologies. Since joining Rhinomed in 2013 he has been responsible for the development of Rhinomed’s nasal technology platform and steering Rhinomed to being one of the world’s leading developers of wearable nasal medical technology. The company has now brought four products to market in the global sleep and snoring, respiratory and nasal congestion markets and is developing applications in the diagnostic and drug delivery markets. Over the course of his career he worked for a wide spectrum of companies from large multinationals through to start-up companies in Life Sciences, Cleantech, Financial Services and the Media and Communication industries. Michael received a Master’s in Entrepreneurship and Innovation (MEI) from Swinburne University and a Bachelor’s degree in Business from Monash University. Michael is a non-executive director of the US based Foundation for Airway Health.
Ron Dewhurst has spent 40 years spread across the Investment Banking and Asset Management Industries. He has worked internationally, including Hong Kong, the United Kingdom, and the United States of America, along with Australia. Ron has held leadership roles as CEO of ANZ McCaughan Ltd, Managing Director of IOOF Holdings Ltd, Head of Americas for J P Morgan Asset Management, and Executive Vice President and Head of Global Investment Managers for Legg Mason Inc.
Ron currently spends his time investing in and developing strategies in early stage companies. Ron has a long history of philanthropic pursuits. Ron is a strong advocate for diversity both broadly in the community, and more specifically in the business environment.
Ron is currently the Chairman of Sprott Inc. (TSX:SII), Executive Chairman and CEO of Cooper Investors Pty Ltd, and an Independent Director of LGIA Super Trustee.
Non executive Director
Brent is an Executive across the media, publishing, technology, consumer, retail and sports industries. Brent spent eighteen years at Nike Inc. including three years as Vice President/Chief Executive Western Europe based in Amsterdam, Vice President & Chief Marketing Officer EMEA, along with other leadership roles in Europe, the USA and Australia in general marketing and management. Brent was the founder and CEO of Unscriptd, a technology led sports media company, which was acquired by New York publisher The Players Tribune in 2018.
Brent is a Non-Executive Director of Kathmandu Holdings Limited (ASX:KAT), and an Executive Director of Enero Group Limited (ASX:EGG).
DR ERIC KNIGHT
Non executive Director
Dr Knight is the Executive Dean of the Macquarie Business School. He has advised clients on strategy formulation and execution in consumer products, healthcare, and media. Eric has significant experience leading cross- functional project teams, as well as international and multidisciplinary research teams. Eric was previously a consultant with the Boston Consulting Group.
Eric has a Bachelor of Arts and Honours in Bachelor of Laws (Honours) both from The University of Sydney, and a Doctor of Philosophy from The University of Oxford, Eric is also a graduate of the Australian Institute of Company Directors, a Fellow of the Royal Society of New South Wales, and a Senior Fellow of the Higher Education Academy.
Assoc. Prof. john mcbain
Non executive Director
Assoc. Prof. McBain is the former Head of Reproductive Services at The Royal Women’s Hospital in Melbourne, Australia. He is also the former President of the Fertility Society of Australia, and was a founder of Melbourne IVF, now Virtus Health (ASX:VRT).
Prof. McBain served as the Chairman of Melbourne IVF and subsequently as a Director of Virtus Health prior to its listing on the ASX. Prof. McBain holds a Medical degree from Glasgow University.
Chief Financial Officer
Sean is an experienced financial executive with over 20 years of experience in senior financial roles including as a Director, Company Secretary and Chief Financial Officer of both private and ASX listed companies. Sean is experienced across the medical devices, technology, sport and financial services sectors. He has a Bachelor of Science in Accounting from Salisbury University in Maryland, USA and a Master of Taxation from University of Melbourne. Sean is a Member of the Institute of Chartered Accountants.
Vice president, sales north america
John’s commitment to the healthcare industry spans across decades, from his career start as a Clinical Sales Representative at Johnson & Johnson to senior management positions leading prominent organisations and consumer brands. Most recently, John served as President and General Manager for North America at Nelsons, the makers of RESCUE Remedy. Prior to that he held executive leadership roles at startup Hello Products and The Mentholatum Company. At each organization John played a key role in the successful launch of new brands and products, including RESCUE Plus Sleep, Hello, and Rohto Eye Drops.
John also served on active duty as an engineer officer in the United States Army, serving in the Buffalo District U.S. Army Corps of Engineers and the Third Infantry Division in Germany. He earned an MBA from Canisius College in Buffalo, New York and a BS in Environmental Engineering from the United States Military Academy at West Point.